Redox responsive nanoparticle encapsulating black phosphorus quantum dots for cancer theranostics

ABSTRACT: Effective cancer treatment puts high demands for cancer theranostics. For cancer diagnostics, optical coherence tomography (OCT) technology (including photothermal optical coherence tomography (PT-OCT)) has been widely investigated since it induces changes in optical phase transitions in tissue through environmental changes (such as temperature change for PT-OCT). In this report, redox responsive nanoparticle encapsulating black phosphorus quantum dots was developed as a robust PT-OCT agent. Briefly, black phosphorus quantum dots (BPQDs) are incorporated into cysteine-based poly-(disulfide amide) (Cys-PDSA) to form stable and biodegradable nanoagent. The excellent photothermal feature allows BPQD/Cys-PDSA nanoparticles (NPs) as a novel contrast agent for high-resolution PT-OCT bioimaging. The Cys-PDSA can rapidly respond to glutathione and effectively release BPQDs and drugs in vitro and in vivo. And the obtained NPs exhibit excellent near-infrared (NIR) photothermal transduction efficiency and drug delivery capacity that can serve as novel therapeutic platform, with very low chemo drug dosage and side effects. Both of the polymer and BPQD are degradable, indicating this platform is a rare PT-OCT agent that is completely biodegradable. Overall, our research highlights a biodegradable and biocompatible black phosphorus-based nanoagent for both cancer diagnosis and therapy. Graphical abstract Image 1 Highlights • Black phosphorus based nanoplatform, the first PT-OCT nanoplatform could be completely degraded in vitro and in vivo.• Black phosphorus quantum dots and chemo drugs have been successfully encapsulated into redox responsive nanoparticles.• Very low dose of PTX (such as 1 mg/kg, 1/10 of normal dose) could achieve excellent therapeutic performance for this platform.

SUBMITTER: Chen H 

PROVIDER: S-EPMC7509833 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature